Nifedipin T20 Retard

Nifedipin T20 Retard

nifedipine

Manufacturer:

Stellapharm

Distributor:

DKSH

Marketer:

Stada
Concise Prescribing Info
Contents
Nifedipine
Indications/Uses
Mild to moderate HTN. Monotherapy or in combination w/ β-blocker for prophylaxis of chronic stable angina pectoris.
Dosage/Direction for Use
Mild to moderate HTN Initially 20 mg once daily, may be increased up to max of 90 mg once daily. Prophylaxis of angina pectoris Initially 30 mg once daily, may be increased up to max of 90 mg once daily.
Administration
May be taken with or without food: Take at the same time each day, preferably in the morning. Swallow whole, do not chew/crush. Avoid grapefruit juice.
Contraindications
Hypersensitivity. Cardiogenic shock, clinically significant aortic stenosis, unstable angina, or MI. Patients w/ history of GI & oesophageal obstruction; Kock pouch; inflammatory bowel disease or Crohn's disease. Concomitant use w/ rifampicin.
Special Precautions
Patient w/ hypotension; poor cardiac reserve. Diabetic patient. Dialysis patients w/ malignant HTN & hypovolaemia. May affect ability to drive & use machines. Impaired liver function. Not to be used during pregnancy. Not recommended during lactation.
Adverse Reactions
Dizziness, flushing, headache, hypotension, peripheral oedema, tachycardia, palpitations; nausea & other GI disturbances, increased micturition frequency, lethargy, eye pain, visual disturbances & mental depression; rashes eg, erythema multiforme, fever & liver function abnormalities eg, cholestasis; gingival hyperplasia, myalgia, tremor & impotence.
Drug Interactions
Increased BP lowering effect of antihypertensives. Deterioration of heart failure w/ β-receptor blockers. Concomitant use w/ CYP450 3A4 inducers eg, cimetidine, diltiazem, fluoxetine. Reduced digoxin clearance & increased plasma digoxin level. Lowered plasma quinidine levels & distinct increase in plasma quinidine levels after discontinuation. Increased BP lowering effect w/ grapefruit juice.
MIMS Class
Calcium Antagonists
ATC Classification
C08CA05 - nifedipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Nifedipin T20 Retard retard tab 20 mg
Packing/Price
10 × 10's
Sign up for Free to continue reading
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in